-- FX006 Exhibits Reduced Systemic Steroid Exposure Compared to Immediate Release Steroid -- WOBURN, Mass., Dec. 17, 2012 -- /PRNewswire/ -- Flexion Therapeutics, Inc. today reported that FX006, its ...

BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone ...

WOBURN, Mass., May 30, 2012 – Flexion Therapeutics, Inc. today reported that its lead osteoarthritis drug candidate, FX005, demonstrated significant pain relief over placebo at four weeks* in a Phase ...

Flexion Therapeutics, Inc.’s FLXN shares rose almost 10.4% on Friday following the FDA approval for its osteoarthritis (OA) knee pain drug, Zilretta. With the approval, the drug becomes the first and ...

BURLINGTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced plans to advance FX201 into the high dose cohort of the Phase 1 dose-escalation trial. The ...

Flexion Therapeutics' FX006, a sustained-release formulation of the steroid triamcinolone, has been able to deliver drug to the knee joint in people with osteoarthritis (OA) for 6 weeks or more. In ...

Please provide your email address to receive an email when new articles are posted on . Flexion Therapeutics Inc. announced the full commercial launch of Zilretta for the management of pain associated ...

Pacira’s acquisition grants them access to Flexion’s pain management portfolio. Pacira BioSciences, a biopharmaceutical company focused on non-opioid pain management, announced that it had acquired ...

With growing sales for Zilretta ® (triamcinolone acetonide extended-release injectable suspension), its first gene therapy candidate expected to generate clinical data before year’s end and another ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...